Key result
Assessment of apolipoprotein AI and B plasma levels alongside triglyceride concentrations aids in coronary heart disease risk prediction and treatment tailoring.
Answers are grounded in this paper and cite their sources.
Reveals how apolipoprotein AI and B levels reflect lipid metabolism and coronary heart disease risk, indicating their utility in tailoring cardiovascular treatment.
Apolipoproteins AI and B are structural components of lipoprotein particles, and also determinants of the metabolic fate of the encapsulated lipid, cholesterol and triglyceride. Development of accurate assays for these apolipoproteins has opened the way for their use as predictors of coronary heart disease risk. Interpretation of AI and apo B levels is best undertaken with background knowledge of the metabolic status of an individual, especially the lipolytic capacity as reflected in the triglyceride concentration. Those with raised triglyceride, in general, not only have an elevated apo B/apo AI ratio, but also apo B-containing lipoproteins with a prolonged residence time and hence ample opportunity for modification and damage. Assessment of apolipoprotein levels is an aid to risk prediction and can be useful in tailoring treatment.
No takes yet. Share an insight, caveat, or question.
Marcovina et al. (2006) conducted a review in Coronary heart disease. Apolipoprotein AI and apolipoprotein B plasma level measurement was evaluated on Coronary heart disease risk prediction. Assessment of apolipoprotein AI and B plasma levels alongside triglyceride concentrations aids in coronary heart disease risk prediction and treatment tailoring.
Synapse has enriched 10 related papers. Consider them for comparative context: